| Date | Title | Description |
| 11.08.2026 | ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer | ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Off... |
| 03.07.2026 | Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B | End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies
End-of-treatment data from ENHANCE did not d... |
| 27.05.2026 | Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV | - Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone
- Data from Cohort 4 suggested that participants responding ... |
| 26.02.2026 | genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model | LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows ... |
| 24.01.2026 | Why NS1 Roofing, Inc. Is the Clear Choice for Your Home | Share
Share
Share
Share
Email
Your roof is more than just shingles and nails. It’s the primary shield that protects your family, your belongings, and your investment from the elements. Yet, for many homeowners, the roof is out of sight and ... |
| 10.11.2025 | Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B | Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα)
Data suggest the potential... |
| 07.11.2025 | Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine | Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy
DURHAM, N.C. and BEIJING, Nov. 7, 2025 /PRNewswire/ -- Brii Biosciences Limited... |
| 14.05.2024 | Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies | DURHAM, N.C. and BEIJING, May 14, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across... |
| 22.03.2024 | Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results | Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy
Integrating R&D, manufacturing and commercial upsides by acquiring fu... |
| 09.11.2023 | Houston startups dominate ‘most-promising’ companies announcement at annual event | Rice University played host this week to the 12th annual Texas Life Science Forum, where life science leaders and startup founders could network, learn and present pitches on their solutions to a wide array of health-related issues.
Hosted ... |
| 09.11.2023 | Annual report ranks 4 Houston tech companies on list of fasting growing businesses | Deloitte just unveiled the fastest-growing technology companies in North America — and four businesses from Houston made the cut.
For the 29th year, 2023 Technology Fast 500 ranked top tech, media, telecommunications, life sciences, and ene... |
| 06.11.2023 | Innovation and new business incubation at the University of Houston’s Technology Bridge is on a roll | When Jacob Thomas first came to the University of Houston’s Technology Bridge in 2016, he knew it was the perfect incubator space to grow his company, Alchemy Sciences. The excellent support infrastructure enabled the fledgling oil recovery... |
| 02.11.2023 | Houston surprisingly plummets in prestigious list of best cities in the world | Economic investments and population growth are definitive highlights of Houston's success over the last year, but they weren't enough to keep it within the top 50 best cities in the world, according to a prestigious report by Canada-based r... |
| 31.10.2023 | Houston-area college shares more details on new biotechnology program, center | Houston's San Jacinto College will roll out a new biotechnology program in early 2024 as it gets closer to its goal of launching the Center for Biotechnology in Generation Park.
In partnership with the Ireland-based National Institute for B... |
| 02.05.2023 | Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention | - |
| 28.02.2023 | Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference | SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. VIR today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases a... |
| 04.07.2022 | Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China | Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBV
Key partnership with Vir enables multitude of combination treatment options as part of Company's str... |
| 21.06.2021 | Encouraging progress of COVID-19 solutions from Switzerland | CHF 1 million for a next-generation vaccine
The University Hospital Basel (USB), the University of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH) are entering into a research collaboration with the startup company Rock... |
| 21.06.2021 | Encouraging progress of COVID-19 solutions from Switzerland | |
| 07.05.2021 | GLAXOSMITHKLINE PLC
GlaxoSmithKline : GSK and Vir Biotechnology announce the start of the EMA rolling review of VIR-7831 (sotrovimab) for the early treatment of COVID-19 | For media and investors only Issued: London UK and San Francisco US
Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID... |
| 07.04.2020 | GlaxoSmithKline Invests $250 Million In Vir Biotechnology As Part Of A Strategic Deal | GlaxoSmithKline and Vir Biotechnology, Inc. announced they have an agreement to enter a partnership to research and develop solutions for coronaviruses. And GSK will be investing $250 million in Vir.
GlaxoSmithKline plc (GSK) and Vir Biotec... |
| 06.04.2020 | GlaxoSmithKline and ARCH-backed Vir Aim to Take on Covid-19 with Antibodies and CRISPR | - |
| 25.03.2020 | Vir Biotechnology to Test COVID-19 Antibody | - |
| 16.03.2020 | Ally Bridge Portfolio News – WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 | SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufa... |
| 12.03.2020 | Biogen, facing Covid-19 outbreak, teams up with Vir Biotechnologies on coronavirus antibodies | Vir’s shares were up 11% on the Nasdaq in mid-day trading Thursday following the news.
Biogen has been hit hard by an outbreak of the coronavirus following a management meeting in Boston two weeks ago. Shortly after the meeting, the company... |
| 04.03.2020 | Alnylam Pharmaceuticals in COVID-19 Partnership with Vir | - |
| 11.10.2019 | ARCH, SoftBank-backed Vir Biotechnology underwhelms with $143 million IPO | George Scangos went back to Wall Street, and came back 700 million pennies short.
Scangos’ vaunted startup Vir Biotechnology raised $143 million in an IPO they hoped would earn $150 million. Shares were priced at $20, the low-end... |
| 10.10.2019 | SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO | By Joshua Franklin, Rebecca Spalding
2 Min Read
NEW YORK (Reuters) - Vir Biotechnology VIR.O priced its initial public offering (IPO) at $20 a share on Thursday, at the bottom end of expectations, the latest underwhelming investment perform... |
| 10.10.2019 | Vir Biotechnology Announces Pricing of Initial Public Offering | - |
| 27.11.2018 | Startup Spotlight: Gates-backed biotech Vir starts its first clinical trial | For a startup founded last year last year, Vir Biotechnology has a lot going for it. At its helm is George Scangos, the former Biogen CEO. It has $500 million from investors — including very early investments from the Bill and Melinda Gates... |
| 31.07.2018 | What corporate culture characteristics make or break startups? | BIOCOM and Slone Partners co-hosted an event called Culture as Cornerstone: Bay Area Perspective – Activating Senior Executives To Build Thriving Cultural Environments.” The focus was on workplace culture – what defines it, what builds it, ... |
| 24.01.2018 | When VCs hand out mega-rounds to Vir and Gossamer, are they betting on the jockey or the horse? | Following a period of unprecedented returns for biopharma investors, flush VCs are sinking bigger and bigger rounds of cash into companies whose pipelines are still in their infancy. Taking this trend to a new level is ... |
| 25.09.2017 | Humabs BioMed acquired by Vir Biotechnology | |
| 18.05.2016 | Celgene backs $10.6M funding round for CRISPR antiviral biotech Agenovir | The J&J incubated Californian biotech Agenovir has raised $10.6 million in its first Series A funding round as it looks to advance work on the hot ticket science of CRISPR/Cas9 in its antiviral research.
The small South San Francisco co... |
| - | Biogen, facing Covid-19 outbreak, teams up with Vir Biotechnologies on coronavirus antibodies | The Marriott Long Wharf Hotel in Boston, where the Biogen conference took place
A large biotechnology company that has seen dozens of its employees fall ill due to the Covid-19 pandemic has signed a deal with a smaller firm to manufacture a... |
| - | What corporate culture characteristics make or break startups? | We’re soldiers now in the culture war. We’re soldiers now, but we don’t know what it’s for. — Arcade Fire
I am fortunate I get to moderate a lot of interesting panel discussions. They are usually about healthcare or investing and occasional... |
| - | Vir Biotechnology | “Vir is leveraging immunologic breakthroughs to address unmet patient needs in infectious disease and beyond.” |
| - | Vir Biotechnology, apoiada pelo SoftBank, capta US$ 143 milhões em IPO | A Vir Biotechnology precificou sua oferta pública inicial (IPO) em US$ 20 por ação nesta quinta-feira, no limite inferior de sua faixa de preço prevista, no mais recente desempenho abaixo do esperado para uma ação apoiada pelo Vision Fund d... |
